Novo Surges 10%

BREAKING: Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks

To Profit From This News, Contact us today, and let us demonstrate how we can elevate your portfolio to new levels

Contact Us: bit.ly/Alpha-Binwani-Capital

Website: alphabinwanicapital.com

#NovoNordisk #Amycretin #ObesityTreatment #WeightLoss

Leave a comment